Coherus Q3 net revenue $74.6M (+27% QoQ); net loss narrows to $39.6M; LOQTORZI approved

Coherus Oncology, Inc.

2023-Q3 EPS reported -$1.79 revenue$165,720,000

Q3 2023 net revenue $74.6M, up 27% from Q2; net loss $39.6M ($0.41/sh) vs $86.7M ($1.11/sh) in Q3 2022.
CIMERLI net sales $40.0M (+50% QoQ); UDENYCA net sales $33.0M (+4% QoQ); YUSIMRY launched with $1.4M Q3 sales.
FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for nasopharyngeal carcinoma; commercial launch expected Q1 2024.
Closed Surface Oncology acquisition on Sep 8, adding clinical-stage anti-IL-27 and anti-CCR8 I-O pipeline assets.
UDENYCA ONBODY BLA resubmitted Oct 4; potential approval late 2023 or early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Coherus Oncology, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 6, 2023, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-017778

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.